[144] ANI Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for ANIP insider sales The filing notifies proposed and recent sales of ANI Pharmaceuticals common stock by an insider. A proposed sale of 52,988 shares through Merrill Lynch on NASDAQ is listed with an aggregate market value of $4,792,058.06 and an approximate sale date of 08/21/2025. The shares were acquired on 11/19/2021 in a company buyout and listed as a compensatory payment. The filing also reports three recent sales by Muthusamy Shanmugam on 08/14/2025, 08/15/2025, and 08/20/2025 totaling 147,012 shares with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information.

Positive

• Broker and exchange details provided (Merrill Lynch; NASDAQ) improving transaction transparency
• Acquisition and payment details disclosed (acquired 11/19/2021 via company buyout; compensatory payment)
• Recent sale proceeds reported for three transactions, enabling verification of amounts

Negative

• Large insider sales reported over consecutive days (147,012 shares sold on 08/14–08/20/2025 plus a proposed 52,988-share sale on 08/21/2025)
• Filing does not state a 10b5-1 plan adoption date (if applicable), so trading-plan protections are not documented in this notice

Insights

Securities Analyst

TL;DR: Multiple sizable insider sales disclosed; routine compliance filing but notable share volumes over several days.

The Form 144 documents a planned sale of 52,988 shares and three recent sales totaling 147,012 shares by an insider, executed through Merrill Lynch on NASDAQ. The filing specifies acquisition date (11/19/2021) and classifies the original acquisition as a company buyout with compensatory payment. From a trading-impact perspective this is a disclosure of insider liquidity events rather than operational news; it provides clear quantities, proceeds for recent sales, and broker details that support market transparency.

Compliance/Risk Analyst

TL;DR: Filing appears procedurally complete and includes required representations; no regulatory exceptions noted.

The notice includes required seller representation that no material nonpublic information is known and identifies the broker, dates, share counts, and acquisition circumstances. It lists aggregate market value for the proposed sale and gross proceeds for recent sales, which aids regulatory traceability. There is no indication in the document of a trading plan adoption date or other 10b5-1 details. The filing contains the standard attestation language regarding criminal penalties for false statements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Merrill Lynch 3455 Peachtree Road Atlanta GA 30326	52988	4792058.06	21688772	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2021	Company Buyout	ANI Pharmaceuticals			52988	08/21/2025	compensatory payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Muthusamy Shanmugam 210 Main Street West Baudette MN 56623	common	08/14/2025	47010	4206603.82
Muthusamy Shanmugam 210 Main Street West Baudette MN 56623	Common	08/15/2025	52990	4618063.56
Muthusamy Shanmugam 210 Main Street West Baudette MN 56623	common	08/20/2025	47012	4243702.53

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider sales did ANI Pharmaceuticals (ANIP) disclose in this Form 144?

The filing reports a proposed sale of 52,988 shares (aggregate market value $4,792,058.06) for sale on 08/21/2025 and three recent sales by Muthusamy Shanmugam on 08/14/2025 (47,010 shares), 08/15/2025 (52,990 shares), and 08/20/2025 (47,012 shares).

Through which broker will the proposed ANIP sale be executed?

The proposed sale lists Merrill Lynch at 3455 Peachtree Road, Atlanta, GA, and names NASDAQ as the securities exchange.

When and how were the shares being sold acquired?

The shares related to the proposed sale were acquired on 11/19/2021 in a company buyout from ANI Pharmaceuticals and the payment is described as a compensatory payment.

What proceeds were reported for recent insider sales?

The filing reports gross proceeds of $4,206,603.82 for 08/14/2025, $4,618,063.56 for 08/15/2025, and $4,243,702.53 for 08/20/2025.

Does the filer assert knowledge of any undisclosed material information?

Yes. By signing the notice the person represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed.